9 registrations that name resveratrol as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 9 registrations
Status
Phase
5US sites across 5 states
1
2 to 4
5 to 19
20 or more
All 9 registrations
RecruitingNCT06585865
Strength Training and Resveratrol
No phase
Texas Tech University
About 36 people
Started Jun 13, 2025
In plain words A study of resveratrol in people 60 and older, run by Texas Tech University. It plans to enroll about 36 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 60 and older; healthy volunteers accepted. Conditions: Sarcopenia; Anabolic Resistance.
Age 60+
Minimally active (less than 1 hour of structured exercise/week other than walking)
No resistance training for the previous 6 months
Not currently taking resveratrol supplements
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Resistance training; Resveratrol 500 mg oral once daily.; Placebo
Registered summary
The main goal of this study is to find out if supplementing with resveratrol improves skeletal muscle adaptations to strengthening exercise (resistance training or strength training) in adults age 60+, and to determine whether circulating vehicles of inter-organ communication (extracellular vesicles) and their cargo might help explain those responses. The investigators will also examine whether resveratrol supplementation improves blood vessel function and cognitive function (brain health) in response to strength training.
Where, as registered
1 US site in 1 state.
RecruitingNCT07592767
RESvEraTrol in Parkinson's Disease (RESET)
Phase 2
Georgetown University
About 30 people
Starts Sep 17, 2026 (estimated)
In plain words A Phase 2 study of resveratrol in people 55 to 85, run by Georgetown University. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 55 to 85. Conditions: Parkinson's Disease.
Capable of providing informed consent (IC) and complying with study procedures
Stable on Levodopa and/or DA agonists for at least 4 weeks before enrollment
Clinical diagnosis of PD according to UK Brain Bank criteria and/or PD with Dementia (PDD) by MDS criteria (53-55).
MoCA≥18.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Trans-Resveratrol
Registered summary
This is an exploratory phase 2a study to investigate two doses of resveratrol (JotrolTM) vs placebo in individuals diagnosed with Parkinson's Disease (PD). Participants (n=30) will be randomized 1:1:1 into 3 groups and will receive oral JotrolTM vs placebo. Study drug will be titrated to reach a final maximal dose per group and will be administered orally once daily (QD) for 3 months. The study will primarily evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics (PK/PD) of JotrolTM.
Where, as registered
1 US site in 1 state.
RecruitingNCT04449198
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
Early phase 1
Augusta University
About 24 people
Started Oct 14, 2020
In plain words An early phase 1 study of resveratrol in people 18 and older, run by Augusta University. It plans to enroll about 24 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Type 1 Diabetes.
Men and premenopausal women
All races
Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)
The exclusion criteria are on the listing.
What it tests, as registered
Resveratrol; Placebo
Registered summary
The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
Where, as registered
1 US site in 1 state.
RecruitingNCT06723119
Effect of Resveratrol Supplementation on Exercise Performance and Recovery
No phase
University of Central Florida
About 20 people
Started Oct 1, 2024
In plain words A study of resveratrol in male participants 18 to 40, run by University of Central Florida. It plans to enroll about 20 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 40; healthy volunteers accepted. Conditions: Effect of Resveratrol on Performance and Recovery.
• Male between the ages of 18-40 years old
Healthy, and ready for physical activity as determined by the PAR-Q+, and MHQ.
Participants will be required to be recreationally active (defined according to ACSM standards of at least 150 minutes exercise per week).
Participants will be required to have been actively resistance training for a minimum of 6 months as defined by 3 resistance training sessions per week with at least one lower body session.
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Resveratrol (VRES) 500 mg oral once daily.; Placebo 500 mg oral once daily.
Registered summary
To examine the effects of once daily supplementation with 500mg VeriSperse® resveratrol (VRES) for 17 days on muscle function, delayed onset muscle soreness, systemic concentrations of muscular damage markers and markers of oxidative stress in resistance trained young adult males following a damaging isoinertial squat protocol (ISP).
Where, as registered
1 US site in 1 state.
RecruitingNCT07089381
Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.
No phase
Ain Shams University
About 118 people
Starts Aug 1, 2025 (estimated)
In plain words A study of resveratrol in people 18 and older, run by Ain Shams University. It plans to enroll about 118 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Rheumatic Arthritis; Rheumatoid Arthritis (RA) Prevention; Inflamation; Antioxidant; Anti Oxidative Stress; Anti Aging; C Reactive Protein; Methotrexate; Quality of Life Outcomes.
Adult patients > 18 years old
Established diagnosis of RA according to American College of Rheumatology/European league Against Rheumatism (ACR/EULAR) 2010 criteria (Aletaha et al., 2010), presented with moderate to high disease activity identified as disease activity…
Patients receiving stable regimen of one or more csDMARDs for at least the past 3 months.
RA Patients with Moderate or high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) >3.2.
The exclusion criteria are on the listing.
What it tests, as registered
Resveratrol 1 gm.; Methotrexate
Registered summary
The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis. Objectives : 1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring: * Serum Sirtuin 1(SIRT1) * Serum Myeloperoxidase (MPO) * Serum C-reactive protein (CRP) 2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score). 3. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07865377
Serum Endogenous Estrogens, Estrogen Receptors, and Sirtuin-1 and -3 After Resveratrol Supplementation
No phase
InCor Heart Institute
About 80 people
Started Aug 24, 2026
In plain words A study of resveratrol in female participants 45 to 70, run by InCor Heart Institute. It plans to enroll about 80 people at 1 site, none in the US.
Trans-resveratrol, 1000 mg daily for 90 days; Placebo
Registered summary
Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality among postmenopausal women. Resveratrol, a phenolic compound with antioxidant properties, may influence lipid metabolism, endothelial function, and platelet aggregation, while sirtuin-1 and sirtuin-3 regulate metabolic and hormonal responses to nutritional stimuli. The full summary is on the listing.
Where, as registered
No US site; Brazil (1).
RecruitingNCT07487623
Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).
No phase
University of Guadalajara
About 26 people
Started Oct 11, 2025
In plain words A study of resveratrol in people 18 to 69, run by University of Guadalajara. It plans to enroll about 26 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 69. Conditions: Liver Disease Chronic; HEPATITIS C VIRUS CHRONIC INFECTION.
What it tests, as registered
resveratrol, quercetin, taurine, whey protein, and inulin; whey protein
Registered summary
The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in patients with liver disease related to chronic hepatitis C infection. The study will compare the investigational supplement with an active control (whey protein alone) to determine whether the combination formulation provides additional benefits on liver-related biomarkers and clinical assessment. The full summary is on the listing.
Where, as registered
No US site; Mexico (2).
Not yet recruitingNCT06470061
RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β
Phase 2
Zaparackas and Knepper LTD
About 200 people
Starts Jul 2024 (estimated)
In plain words A Phase 2 study of resveratrol in people 50 to 90, run by Zaparackas and Knepper LTD. It plans to enroll about 200 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 90; healthy volunteers accepted. Conditions: Alzheimer Disease; Mild Cognitive Impairment; Cognitive Decline.
50-90 years of age at screening.
Male or female
Any race or ethnicity.
Provide written informed consent.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Resveratrol, Quercetin, and Curcumin (RQC); Curcumin
Registered summary
The goal of this clinical trial is to evaluate whether oral resveratrol, quercetin, and curcumin (RQC) can prevent the accumulation of retinal amyloid-β and/or cognitive decline over 24 months in adults aged 50-90 with Stage 1 or 2 Alzheimer's disease as described in FDA-2013-D-0077. The trial will also evaluate the safety and tolerability of RQC. Curcumin, which binds to amyloid-β, will act as a fluorescent label to identify retinal amyloid-β in vivo using optical coherence tomography (OCT)-autofluorescence imaging. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT06779214
Effect of Food-derived Active Components on Digestive Tract Health in Adults with Irritable Bowel Syndrome
No phase
Peking University
About 180 people
Starts Feb 28, 2025 (estimated)
In plain words A study of resveratrol in people 18 to 60, run by Peking University. It plans to enroll about 180 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Irritable Bowel Syndrome - Diarrhoea.
met the Western Medicine Rome IV diagnostic criteria for diarrheal IBS
The goal of this clinical trial is to learn if Bifidobacterium. animalis subsp. Lactis A6 Strain or resveratrol to improve the symptoms of diarrhea-predominate irritable bowel syndromes (IBS-D). The main questions it aims to answer are: 1. Does Bifidobacterium animalis subsp.Lactis A6 Strain or resveratrol improve the symptoms of IBS-D. 2. What is the optimal intervention dose of Bifidobacterium. animalis subsp.Lactis A6 Strain or resveratrol to improve IBS-D Researchers will compare Bifidobacterium. The full summary is on the listing.